Wells Fargo Maintains Equal-Weight on Myriad Genetics, Lowers Price Target to $5.5
Benzinga Newsdesk 6 months ago
NewsPrice TargetAnalyst Ratings
Wells Fargo analyst Brandon Couillard maintains Myriad Genetics (NASDAQ:MYGN) with a Equal-Weight and lowers the price target from $6 to $5.5.
Wells Fargo analyst Brandon Couillard maintains Myriad Genetics (NASDAQ:MYGN) with a Equal-Weight and lowers the price target from $6 to $5.5.